Histopathology Medium with IHC Analysis at Lahore PCR Lab

Histopathology Medium with IHC Analysis at Lahore PCR Lab

Histopathology combined with Immunohistochemistry (IHC) represents the absolute pinnacle of diagnostic accuracy in modern pathology, providing critical, life-saving insights for patients and clinical teams. At Lahore PCR Lab, located in the heart of Lahore, Pakistan, this highly specialized diagnostic service is dedicated to the evaluation of medium-sized tissue specimens. Histopathology is the microscopic study of diseased tissue, allowing pathologists to observe structural changes, cellular abnormalities, and tissue architecture. While traditional staining methods like Hematoxylin and Eosin (H&E) provide the foundational morphological diagnosis, Immunohistochemistry (IHC) introduces an advanced layer of molecular precision. By utilizing highly specific, laboratory-engineered antibodies, IHC identifies the presence, localization, and concentration of specific proteins (antigens) within the tissue cells. This allows pathologists to characterize tumors and other complex diseases at a molecular level, transforming subjective microscopic observations into objective, definitive, and clinically actionable diagnoses.

The clinical importance and diagnostic value of Histopathology Medium with IHC at Lahore PCR Lab cannot be overstated. It is the gold standard for distinguishing between benign and malignant lesions, subtyping complex cancers such as lymphomas and sarcomas, identifying the primary organ of origin in metastatic tumors of unknown primary, and determining the expression of critical prognostic and therapeutic biomarkers. For example, in breast cancer cases, IHC is routinely performed to assess Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2/neu expression, which directly dictates whether a patient will receive hormone therapy, chemotherapy, or targeted monoclonal antibody treatments. By utilizing state-of-the-art automated IHC staining platforms and high-resolution light microscopy, Lahore PCR Lab ensures that patients in Lahore and across Pakistan receive the most accurate, reliable, and timely diagnostic reports to guide their treatment journeys.

Clinical Procedure: What to Expect

Patient Preparation

Because a Histopathology Medium with IHC test is performed on a tissue specimen that has already been surgically removed during a biopsy or surgical resection, there is no direct physical preparation required from the patient at the time of laboratory analysis. However, ensuring the integrity and proper handling of the specimen is vital for securing an accurate diagnostic result. Patients and referring clinical teams must adhere to the following strict guidelines:

• Specimen Submission: Patients must submit the formalin-fixed paraffin-embedded (FFPE) tissue block, commonly referred to as the paraffin block, along with all corresponding glass slides prepared from the initial surgical procedure.
• Clinical Documentation: It is mandatory to provide a comprehensive clinical history, including the patient’s age, gender, primary symptoms, radiological findings (such as CT, MRI, or ultrasound reports), surgical notes, and any previous pathology reports. This clinical context is invaluable to the interpreting pathologist.
• Fixation Standards: The tissue specimen must have been placed in 10% neutral buffered formalin immediately after surgical removal. Any delay in fixation or the use of incorrect fixatives can lead to protein degradation, resulting in false-negative IHC staining.
• No Physical Restrictions: Since the patient is not physically undergoing a procedure at the laboratory, there are no dietary restrictions, fasting requirements, or physical preparations necessary for submitting the tissue block.

During the Procedure

The processing of a Histopathology Medium with IHC specimen at Lahore PCR Lab involves a highly controlled, multi-step scientific workflow executed by expert histotechnologists and interpreted by consultant pathologists:

• Accessioning and Verification: Upon receipt, the tissue block and slides are cross-referenced with the referral form to ensure absolute patient identification, specimen integrity, and clinical history completeness.
• Microtomy: The paraffin block is mounted on a high-precision microtome, and ultra-thin sections measuring 3 to 5 microns are cut and mounted onto specialized, positively charged glass slides designed to prevent tissue detachment during staining.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents to remove the paraffin wax, followed by sequential alcohol washes to rehydrate the tissue.
• Antigen Retrieval: Formalin fixation can mask target proteins. To reverse this, slides undergo antigen retrieval using heat-induced epitope retrieval (HIER) in specific buffer solutions, exposing the target antigens for antibody binding.
• Antibody Incubation: Highly specific primary antibodies are applied to the tissue sections. If the target protein is present, the antibody binds to it. A secondary antibody conjugated with an enzyme is then applied to bind to the primary antibody.
• Visualization: A chromogen substrate is added, reacting with the enzyme to produce a visible colored precipitate (usually brown) at the site of the target protein. The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, and coverslipped.
• Microscopic Evaluation: A consultant pathologist evaluates the slides under a high-power microscope, assessing the staining intensity, cellular localization, and percentage of positive cells to formulate a definitive diagnosis.

When is a Histopathology Medium with IHC Performed?

1. Differentiation of Benign vs. Malignant Tumors

Physicians frequently request Histopathology with IHC when routine microscopic evaluation cannot definitively distinguish between benign cellular proliferation and malignant neoplasia. In complex breast, prostate, or skin biopsies, the presence or absence of specific cellular layers is critical. Pathologists utilize IHC markers like p63, cytokeratins, or AMACR to highlight these structures, allowing them to confirm or rule out invasive carcinoma with absolute clinical certainty, preventing over-treatment or under-treatment.

2. Subtyping of Lymphomas and Hematological Malignancies

Lymphomas represent a highly diverse group of malignancies with vastly different clinical courses and treatment protocols. When a patient presents with persistent lymphadenopathy, fever, and weight loss, a lymph node biopsy is performed. Because different lymphoma subtypes can appear morphologically identical under standard H&E staining, clinicians rely on an extensive IHC panel (including CD3, CD20, CD30, CD15, and Ki-67) to classify the disease into specific B-cell, T-cell, or Hodgkin lymphoma subtypes, enabling targeted therapy.

3. Identification of Primary Tumor in Metastatic Disease

In cases of Cancer of Unknown Primary (CUP), patients present with metastatic tumors in organs like the liver, lungs, or bones without an obvious primary source. To identify the origin without subjecting the patient to invasive exploratory surgeries, pathologists perform IHC on the metastatic biopsy. Lineage-specific markers such as CK7, CK20, TTF-1, CDX2, and Pax-8 help trace the cellular lineage back to the primary organ, allowing oncologists to initiate site-specific chemotherapy.

4. Determination of Therapeutic Targets and Prognostic Markers

Modern oncology is built upon the foundation of personalized medicine. In diagnosed malignancies of the breast, lung, stomach, and colon, IHC is performed to detect specific therapeutic targets. Evaluating HER2/neu expression, estrogen receptors, or PD-L1 expression helps oncologists determine if the patient is a candidate for targeted monoclonal antibodies, hormonal therapies, or immunotherapy, which significantly improves survival rates and minimizes unnecessary side effects.

5. Diagnosis of Atypical Infectious and Inflammatory Conditions

Not all tissue masses are neoplastic; some are caused by atypical infectious agents or complex inflammatory diseases. When standard histochemical stains fail to identify a pathogen in a granulomatous or inflammatory lesion, IHC can be employed. Specific antibodies against viral proteins (such as Cytomegalovirus or Epstein-Barr Virus) or bacterial antigens (such as Helicobacter pylori) allow for the direct, highly sensitive visualization of pathogens within the tissue matrix, guiding targeted antimicrobial therapy.

What Does a Histopathology Medium with IHC Detect?

Histopathology Medium with IHC is capable of detecting a wide array of cellular proteins, genetic alterations, and pathological entities. Some of the most clinically significant findings include:

• Estrogen Receptor (ER) Positivity: Confirms hormone-receptor-positive breast carcinoma, indicating suitability for endocrine therapy.
• Progesterone Receptor (PR) Positivity: Works in conjunction with ER status to guide prognostic assessment in breast oncology.
• HER2/neu Overexpression (Score 3+): Identifies gene amplification in breast and gastric cancers, indicating eligibility for trastuzumab therapy.
• Ki-67 Proliferation Index: Measures the percentage of actively dividing cells, helping to grade tumor aggressiveness.
• CD20 Positivity: Confirms B-cell lineage in non-Hodgkin lymphomas, guiding the use of rituximab.
• CD3 Positivity: Establishes T-cell lineage in lymphoproliferative disorders.
• TTF-1 (Thyroid Transcription Factor-1) Expression: Identifies primary lung adenocarcinoma or thyroid carcinoma in metastatic lesions.
• CDX2 Expression: Indicates a primary gastrointestinal (colorectal) origin of metastatic adenocarcinoma.
• PSA (Prostate Specific Antigen) Positivity: Confirms prostatic origin in metastatic epithelial malignancies.
• CD117 (c-KIT) and DOG1 Positivity: Diagnoses Gastrointestinal Stromal Tumors (GIST), enabling targeted therapy with imatinib.
• S100, Melan-A, and SOX10 Positivity: Confirms the diagnosis of malignant melanoma in poorly differentiated tumors.
• Synaptophysin and Chromogranin A Expression: Identifies neuroendocrine differentiation in tumors of various organ systems.
• p40 and p63 Expression: Confirms squamous cell differentiation in lung and skin malignancies.
• Calretinin and WT1 Positivity: Differentiates mesothelioma from pulmonary adenocarcinoma.
• ALK (Anaplastic Lymphoma Kinase) Fusion Protein: Detects specific translocations in lung adenocarcinoma and anaplastic large cell lymphoma.
• Mismatch Repair (MMR) Protein Deficiency (MLH1, MSH2, MSH6, PMS2): Screens for Lynch syndrome and identifies candidates for immunotherapy.
• Cytomegalovirus (CMV) Antigens: Detects active viral infection in immunocompromised patients’ tissue biopsies.
• Helicobacter pylori Antigens: Confirms chronic active gastritis associated with H. pylori infection.
• Vimentin Expression: Identifies mesenchymal origin, helping to classify sarcomas.
• Desmin and Myogenin Positivity: Confirms rhabdomyosarcoma or skeletal muscle differentiation.
• E-cadherin Loss: Differentiates lobular breast carcinoma (negative) from ductal breast carcinoma (positive).
• Calcitonin Expression: Diagnoses medullary thyroid carcinoma.
• Glutamine Synthetase and Glypican-3 Positivity: Differentiates hepatocellular carcinoma from benign hepatic lesions.
• CD15 and CD30 Positivity: Confirms classic Hodgkin Lymphoma in Reed-Sternberg cells.
• Oct4 and SALL4 Positivity: Identifies germ cell tumors, such as seminomas.

Turnaround Time and Report Access at Lahore PCR Lab

The processing of a Histopathology Medium with IHC specimen is a meticulous, multi-day procedure that cannot be rushed without compromising diagnostic accuracy. At Lahore PCR Lab, the standard turnaround time for this complex analysis typically ranges from 5 to 7 working days. This timeframe allows for proper tissue sectioning, automated antigen retrieval, sequential antibody incubation, and detailed microscopic evaluation by a consultant pathologist. In complex cases requiring consensus reviews or additional antibody stains, the timeline may be extended to ensure the highest diagnostic precision.

Lahore PCR Lab is committed to providing seamless and convenient access to diagnostic reports. Once the consultant pathologist finalizes and signs the report, patients and referring physicians receive an automated SMS notification. Reports can be securely downloaded online via the official Lahore PCR Lab web portal or mobile application. Physical copies of the reports, complete with high-resolution microscopic images if applicable, can also be collected directly from the laboratory’s main facility or designated collection centers across Lahore.

Histopathology Medium with IHC Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Tissue Architecture (H&E)	Intact basement membrane, orderly cellular maturation, and normal stromal relationships.	Disrupted architecture, stromal invasion, cellular pleomorphism, and atypical mitotic figures.
Estrogen Receptor (ER) Status	Negative or low physiological expression in normal breast epithelial cells.	Strong nuclear positivity in malignant epithelial cells, indicating hormone-receptor-positive breast cancer.
HER2/neu Protein Expression	Score 0 or 1+ (no staining or faint, incomplete membranous staining).	Score 3+ (strong, complete, circumferential membranous staining in >10% of tumor cells).
Ki-67 Proliferation Index	Low proliferation rate (typically less than 5% in resting tissues).	Elevated index (e.g., >30% to 90%), indicating highly proliferative and aggressive neoplastic growth.
Lineage Markers (CD20 / CD3)	Normal, compartmentalized distribution of B-cells and T-cells in lymphoid tissues.	Monoclonal expansion of CD20+ B-cells or CD3+ T-cells, indicating B-cell or T-cell lymphoma.
Melanocytic Markers (SOX10 / Melan-A)	Negative in non-melanocytic tissues; confined to normal melanocytes in skin.	Diffuse, strong cytoplasmic and nuclear positivity in metastatic lesions, confirming melanoma.
Mismatch Repair (MMR) Proteins	Intact nuclear expression of MLH1, MSH2, MSH6, and PMS2.	Loss of expression in one or more MMR proteins, indicating microsatellite instability (MSI-High).
Neuroendocrine Markers (Synaptophysin)	Negative in non-neuroendocrine tissues.	Strong, diffuse cytoplasmic positivity, confirming neuroendocrine tumor differentiation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Histopathology Medium with IHC?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists with specialized training in oncopathology and immunohistochemistry.
• Advanced Diagnostic Approach: We utilize state-of-the-art automated IHC staining platforms that ensure consistent, highly reproducible, and standardized results.
• Comprehensive Antibody Panel: Lahore PCR Lab maintains an extensive inventory of primary and secondary antibodies to address complex diagnostic dilemmas.
• Commitment to Accurate Diagnosis: We implement rigorous internal and external quality control protocols to maintain the highest standards of diagnostic accuracy.
• Professional Reporting: Our reports are highly detailed, clinically integrated, and designed to provide oncologists with clear, actionable therapeutic targets.
• Comfortable Environment: We offer a professional and supportive environment for patients submitting specimens and seeking diagnostic consultations.
• Convenient Location: Strategically located in Lahore, Pakistan, our laboratory is easily accessible for patients and clinical couriers from all parts of the city.
• Patient-Focused Care: We provide dedicated support channels to guide patients through specimen submission, billing, and digital report retrieval.